Correction: *Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction*

Landewé RB, van der Heijde D, Dougados M, *et al.* Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. *Ann of Rheum Dis* 2020;79:920–8

A citation to the following paper should be included after first mention of the copyrighted SPARCC instrument: Maksymowych WP, *et al.* Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. *Arthritis Rheum* 2005;53(5):703–9. doi: 10.1002/art.21445.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2020;79:e120. doi:10.1136/annrheumdis-2019-216839corr1